Weiss Multi-Strategy Advisers’s Acadia Pharmaceuticals ACAD Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-30,500	Closed	-$787K	–	659
2021 Q1	$787K	Buy	+30,500	New	+$1.34M	0.02%	512
2016 Q2	–	Sell	-10,000	Closed	-$280K	–	401
2016 Q1	$280K	Buy	+10,000	New	+$218K	0.01%	415
2014 Q2	–	Sell	-20,000	Closed	-$487K	–	710
2014 Q1	$487K	Buy	+20,000	New	+$506K	0.01%	672
2013 Q3	–	Sell	-30,000	Closed	-$545K	–	892
2013 Q2	$545K	Buy	+30,000	New	+$413K	0.02%	462

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Weiss Multi-Strategy Advisers's ACAD Position: Q2 2022 in Review

Weiss Multi-Strategy Advisers sold out of Acadia Pharmaceuticals (ACAD) in Q2 2022, closing a stake of 12,500 shares — an estimated $303K sold.

Weiss Multi-Strategy Advisers first reported a position in ACAD in Q2 2013 and held it in 35 quarters. The position peaked at $7.04M in Q4 2020. 245 funds tracked by Wall St. Rank hold ACAD as of Q2 2022.

Weiss Multi-Strategy Advisers reported no remaining Acadia Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Weiss Multi-Strategy Advisers sold 12,500 Acadia Pharmaceuticals shares in Q2 2022, an estimated $303K.
Weiss Multi-Strategy Advisers first reported a position in Acadia Pharmaceuticals in Q2 2013 and held it in 35 quarters.
Weiss Multi-Strategy Advisers's Acadia Pharmaceuticals position peaked at $7.04M in Q4 2020.
245 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2022.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q2 2022, filed 15 Aug 2022.